Summary: Neuron-specific enolase and carcino-embryonic antigen were quantified simultaneously in sera of 135 patients attending the Department of Respiratory Diseases for diagnostic bronchoscopy. Fifteen small cell lung carcinomas, 24 non-small cell lung carcinomas and 96 benign pulmonary diseases were investigated. Lung biopsies or bronchial washings were obtained from about 75% of the patients, including all patients with neoplastic diseases. Serum neuron-specific enolase was measured by a recently introduced enzymeimmuno assay (WaKo NS-Enolase EIA-II testkit). The results obtained with this kit were similar to those based on RIA assays.
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Materials and Methods

Patients
A total of 135 patients, attending the Department of Respiratory Diseases of the De Wever Hospital for diagnostic bronchoscopy, participated in this study. Biopsies or bronchial washings were obtained from about 75% of these patients, including all with apparent bronchoscopic abnormalities. Histological and cytological examinations performed by the Department of Pathology diagnosed small cell lung carcinomas (10 limited and 5 extended cases) or non-small cell lung carcinomas. Patients were classified in one of the categories, small cell lung carcinomas (n = 15), non-small cell lung carcinomas (n = 24) or benign pulmonary diseases (n = 96). Serum samples were obtained before the start of treatment. A number of small cell lung carcinoma patients was followed during chemotherapy, and serum samples were obtained two days before onset of the chemotherapy cycles.
Neuron-specific enolase analysis Serum samples, free of haemolysis, were stored at -20 °C until analysis. Neuron-specific enolase was quantified with the WaKO NS-Enolase (EIA)-II testkit from Amano Pharmaceutical Co (Distributor WaKo Pure Chemical Ind. Ltd., Osaka, Japan; Code No. 991-20001). In brief, neuron-specific enolase is bound to polyclonal rabbit anti-bovine neuron-specific enolase antibody immobilized to polystyrene beads. A sandwich is formed with -.D-galactosidase-labelled monoclonal murine anti-neuron-specific enolase. After washing, the release of chlorophenol red from chlorophenol red--D-galactopyranoside was measured photometrically. The reported neuron-specific enolase concentrations are the means of duplicate analyses.
Results
In our evaluation of the WaKo neuron-specific enolase kit we found intra-and inter-run coefficients of variation that agreed with those quoted by the manufacturers data, i. e. about 3 to 7% within run and 4 to 7% between runs. The analytical range is 1.7 to 135.0 μg/l. Higher concentrations were measured after dilution of the sample with 9 g/1 saline solution. The results of the neuron-specific enolase analyses are presented in figure 1 . The mean neuron-specific enolase concentration for 5 patients with extensive small cell lung carcinomas was 88.2 μg/l. For limited small cell lung carcinomas (n = 10) and for non-small cell lung carcinomas (n = 24), the mean neuron-specific enolase concentrations were 18.0 μg/l and 6.6 μg/l, respectively.
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Statistical analysis
Non-parametric tests were applied. The Wilcoxon two-sample test was used for testing tumour-marker level differences in patient subgroups. The Spearman rank correlation test was used for testing correlation between neuron-specific enolase and carcino-embryonic antigen concentrations.
The neuron-specific enolase levels in the pre-treatment samples of the extended small cell lung carcinoma group were significantly higher than in the limited small cell lung carcinoma group according to the Wilcoxon test (p < 0.01). We found no significant difference between the levels of carcino-embryonic antigen in the extended small cell lung carcinoma and the limited small cell lung carcinoma group (Wilcoxon test, ρ < 0.05).
Neither a positive nor a negative correlation could be detected between the neuron-specific enolase and the carcino-embryonic antigen levels in the sera of the whole small cell lung carcinoma group (n = 15) (Spearman rank test, ρ < 0.01). In order to compare the discriminating abilities of neuron-specific enolase and carcino-embryonic antigen, both for small cell lung carcinomas and non-small cell lung carcinomas, ROC curves were constructed (figs. 2 and 3).
As shown by figure 2, neuron-specific enolase clearly has advantages over carcino-embryonic antigen for the detection of small cell lung carcinomas. Based on the ROC curve an optimal cutoff value of 10 μg/l was selected (asterisk in fig. 2 ). At this cutoff value the sensitivity and specificity were 87% and 88%, respectively. The maximal value for the sum of sensitivity and specificity was about 180% for neuron-specific enolase in small cell lung carcinomas. For carcinoembryonic antigen the maximal sum was about 130% in small cell lung carcinomas. The test efficiency for neuron-specific enolase in small cell lung carcinoma detection, defined as the number of true positives plus the number of true negatives divided by the total number of patients, was 89% at the cutoff value 10. As shown in figure 3 , the measurement of serum neuron-specific enolase has no value for the detection of non-small cell lung carcinomas, while carcino-embryonic antigen has at least some discriminating ability. The maximal sum of sensitivity and specificity was about 110% for neuron-specific enolase and 140% for carcino-embryonic antigen in non-small cell lung carcinomas.
Follow up of patients
Longitudinal analyses were performed for a number of small cell lung carcinoma patients. The results for a case of limited small cell lung carcinoma and extended small cell lung carcinomas are presented. Patient F-L ( fig. 4 ) was a 70 year old woman with the diagnosis of limited small cell lung carcinoma, who showed a partial remission after 5 chemotherapy cycles. However, after 8 months a relapse was noticed with cerebral and liver metastases and greatly increased neuron-specific enolase levels. Patient Μ ( figure 5 ) was a 70 year old man with the diagnosis of extended small cell lung carcinoma with bone and liver metastases. Partial remission was seen after 5 chemotherapy cycles. No tumour could be found at bronchoscopy or X-thorax at 7 months after the initial diagnosis. However, 3 months later a relapse occurred with a sharp increase in neuron-specific enolase. 
Discussion
After the first report by Carney et al. (1) on the diagnostic benefits of neuron-specific enolase in small cell lung carcinomas, a number of studies have been performed on this subject. In most studies RIA methods have been employed for the neuron-specific enolase analysis. In table 1 a literature survey (9 -22) is presented with emphasis on serum neuron-specific enolase in small cell lung carcinomas. The presence of high neuron-specific enolase levels in neuroblastomas and other malignancies (5, 8) is beyond the scope of our study.
It can be seen from table 1 that neuron-specific enolase is useful for detecting and monitoring small cell lung carcinomas. A comparison of the various studies is, however, difficult, due to differences in methods and selection of cutoff values (range 6 -20 μg/l). Many authors used a cutoff value derived from the "normal values" of a reference population: mean plus two or three standard deviations. Other authors used quite arbitrary levels. For example a 25 μg/l cutoff value was chosen as a "more discriminative limit" (4, 9, 10).
Improvement of specificity inherently leads to a decreased sensitivity of the tumour marker, as shown by ROC curves (6, 7) . It must be kept in mind that especially the specificity data are dependent on the reference (control) group used, as demonstrated in table 1. In our opinion it is preferable to consider a random group of patients elected for bronchoscopy, including possible lung-carcinomas as a reference for evaluating neuron-specific enolase and small cell lung carcinomas, instead of a group of healthy controls or patients with unrelated diseases. In figure 2 all patients without the diagnosis small cell lung carcinoma or non-small cell lung carcinoma, served as the reference group.
The optimal cutoff value for neuron-specific enolase, defined as the highest level corresponding to nondisease, was derived from figure 2 (10 μg/l). Although our cutoff value was obtained by a completely different approach, it is equal to the one used by Gerbitz (17) and Tamura (22) for their RIA assays. In general the cutoff values used in RIA methods are higher than in El A methods (tab. 1). Methodological differences include the use of polyclonals versus monoclonals, or possibly measurement of the αγ-isoenzyme as well as the γγ-isoenzyme (e. g. 1. c. (26)). The WaKo kit is based on a monoclonal antibody specific for the γγ-isoenzyme. The frequently used Pharmacia RIA assay is based on polyclonal antibodies binding the αγ as well as the γγ-isoenzyme. Table 2 presents a survey of literature on serum carcino-embryonic antigen levels in small cell lung carcinomas and non-small cell lung carcinomas (11, 18, 22 -25) . As in the studies using neuron-specific enolase, a comparison of data is difficult, owing to differences in methods and selection of cutoff values. From the ROC curve presented in figure 2 we derived a 2.5 μg/l cutoff value, which is lower than in other studies (tab. 2).
In our study the generally used tumour marker, carcino-embryonic antigen, appeared to be of less value for small cell lung carcinomas than the more specific marker, neuron-specific enolase (see fig. 2 ). Waalkes (25) found that pretreatment carcino-embryonic antigen levels generally showed a correlation with the stage of the disease and "not uncommonly" rose at the relapse. However, later studies favoured neuronspecific enolase rather than carcino-embryonic antigen for the detection and follow-up of small cell lung carcinomas. The same conclusion can be drawn from a comparison of the data in the tables 1 and 2.
It can be concluded from an extensive literature survey that the results obtained with the WaKo kit for neuron-specific enolase are very similar to those published for RIA or other EIA methods. Neuron-specific enolase analysis is clearly superior to carcino-embryonic antigen in the diagnosis of small cell lung carcinoma. Extended small cell lung carcinoma corresponds to significantly higher neuron-specific enolase levels than limited small cell lung carcinoma. Neuron-specific enolase measurements are useful in the follow-up of 
